Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemic

Saved in:
Bibliographic Details
Published in:Thrombosis research 2021-01, Vol.197, p.192-194
Main Authors: Patel, Rachna, Czuprynska, Julia, Roberts, Lara N., Vadher, Bipin, Rea, Catherine, Patel, Raj, Gee, Emma, Saul, Gabrielle, Coles, Evelyn, Brown, Alison, Byrne, Rosalind, Speed, Vicky, Patel, Jignesh P., Arya, Roopen
Format: Article
Language:English
Subjects:
Administration, Oral
Anticoagulants - adverse effects
Anticoagulants - therapeutic use
Coagulation and Fibrinolysis
Counseling
COVID-19 - blood
COVID-19 - complications
COVID-19 - epidemiology
COVID-19 - prevention & control
Drug Monitoring
Drug Substitution - methods
Hospitals, University - organization & administration
Hospitals, University - statistics & numerical data
Humans
Informed Consent
London - epidemiology
Pandemics
Patient Acceptance of Health Care
Patient Education as Topic
Pyridines - adverse effects
Pyridines - therapeutic use
Quarantine
Rivaroxaban - adverse effects
Rivaroxaban - therapeutic use
SARS-CoV-2
Telemedicine
Tertiary Care Centers - organization & administration
Tertiary Care Centers - statistics & numerical data
Thiazoles - adverse effects
Thiazoles - therapeutic use
Thrombophilia - drug therapy
Thrombophilia - etiology
Warfarin - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0049-3848
1879-2472
DOI:10.1016/j.thromres.2020.11.004